Details for Patent: 7,622,470

Which drugs does patent 7,622,470 protect, and when does it expire?

Patent 7,622,470 protects FOLOTYN and is included in one NDA.

This patent has thirty-one patent family members in twenty-three countries.

Summary for Patent: 7,622,470

Title:	Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin
Abstract:	T cell lymphoma is treated by administering to a patient suffering from T cell lymphoma a therapeutically effective amount of 10-propargyl-10-deazaaminopterin. Remission is observed in human patients, even with drug resistant T cell lymphoma at weekly dosages levels as low as 30 mg/m.sup.2. In general, the 10-propargyl-10-deazaaminopterin is administered in an amount of from 30 to 275 mg/m.sup.2 per dose.
Inventor(s):	O'Connor; Owen A. (Scarsdale, NY), Sirotnak; Francis M. (Hampton Bays, NY)
Assignee:	Sloan-Kettering Institute for Cancer Research (New York, NY)
Application Number:	11/141,868
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,622,470
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;

Drugs Protected by US Patent 7,622,470

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Acrotech Biopharma	FOLOTYN	pralatrexate	SOLUTION;INTRAVENOUS	022468-001	Sep 24, 2009		RX	Yes	No						TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
Acrotech Biopharma	FOLOTYN	pralatrexate	SOLUTION;INTRAVENOUS	022468-002	Sep 24, 2009		RX	Yes	Yes						TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA

International Family Members for US Patent 7,622,470

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E405272
Australia	2005249516
Brazil	PI0510895
Canada	2565968
China	102824346